European Drug Report 2025: Trends and Developments: source data
This data bundle contains all of the source data tables for the European Drug Report 2025: Trends and Developments. These data tables are used to generate the data visualisations and other tables in the report. Links to the source data tables to create data visualisations for specific sections can also be found at the bottom of each page, as well as, in most cases, beneath each graphic.
Notes:
- Note that the data set presented on this page is only a small subset of the data collected through our partner organisations. For more data and statistics, as well as for detailed methodological notes, caveats, please consult the Statistical Bulletin 2025, launched alongside this report.
- Unless otherwise stated, all data sets are fully compatible with the Creative Commons Attribution 4.0 International (CC BY 4.0) licence. This means you are free to re-use our data and statistic in your work and research, provided you acknowledge us as the source.
- All files are in CSV (comma separated values) format which may be open by most spreadsheet or statistical software.
Methodological notes
Prevalence of drug use data
- Tmost recent country-level data are based on studies carried out between 2013 and 2024.
- Prevalence estimates for the general population: age ranges are 18-64 and 18-34 for Germany, Greece, France, Italy and Hungary; 16-64 and 16-34 for Denmark, Estonia, Norway, and Sweden; 18-65 for Malta.
- Table EDR25-GPS-1. Prevalence of drug use in Europe, based on most recent general population surveys (2023 or most recent year)
- Table EDR25-GPS-2. Prevalence of drug use in Europe, trends
- Table EDR25-WW-1 Mean weekly measurements by targeted substance from wastewater analysis in selected European cities in 2024, in
- Table EDR25-TDI-1. Treatment demand indicator (TDI) source data, client characteristics, European Drug Report, 2025. Percentages except where otherwise stated
- Table EDR25-Sup-1. Number of reported drug seizures, breakdown by drug, 2023
- Table EDR25-Sup-2. Drug seizures in the European Union — number of drug seizures, indexed trends (2013 = 100)
- Table EDR25-Sup-3. Drug seizures in the European Union — quantity of drugs seized, indexed trends (2013 = 100)
- Table EDR25-Sup-4. Drug seizures in the European Union — number of seizures in 2023
- Table EDR25-Sup-5. Drug seizures in the European Union — quantity seized in 2023 (tonnes)
- Table EDR25-Sup-6. Drug law offences — possession/use offences, indexed trends (2013 = 100)
- Table EDR25-Sup-7. Drug law offences — supply offences, indexed trends (2013 = 100)
- Table EDR25-Sup-8. Drug law offences — number of offences, supply and use/possession, 2023
- Table EDR25-Sup-9. Summary of seizures of EU scheduled precursors and non-scheduled chemicals used for selected drugs produced in the European Union, 2023
- Table EDR25-Sup-10. Quantity of scheduled precursors (EU) and key non-scheduled chemicals seized in the EU (2012-2023), European Drug Precursors Database, 2025
- Table EDR25-Sup-11. Quantities of EU-scheduled precursors and key non-scheduled chemicals seized in the EU in 2023 (kilograms), by their association with drug production
- Table EDR25-Sup-11. Quantities of key precursor chemicals seized in the EU in 2023 (litres), by association with drug production
- Table EDR25-Cannabis-3. Trends in first-time entrants, cannabis, selected countries
- Table EDR25-Cannabis-4. Cannabis markets seizures source data
- Table EDR25-Cannabis-5. Trends in the number of cannabis seizures and quantity of illicit drugs seized (x 1000)
- Table EDR25-Cannabis-6. Trends in the quantities of cannabis seizures and quantity of illicit drugs seized (tonnes)
- Table EDR25-Cannabis-7. Price, potency data for cannabis
- Table EDR25-Cannabis-8. Price and purity/potency indexed trends
- Table EDR25-Cocaine-3. Trends in first-time entrants, cocaine, selected countries
- Table EDR25-Cocaine-4. Cocaine markets seizures source data
- Table EDR25-Cocaine-5. Trends in the number of cocaine seizures and quantity of illicit drugs seized (x 1000)
- Table EDR25-Cocaine-6. Trends in the quantities of cocaine seizures and quantity of illicit drugs seized (tonnes)
- Table EDR25-Cocaine-7. Price, potency data for cocaine
- Table EDR25-Cocaine-8. Price and purity/potency indexed trends
- Table EDR25-Cocaine-9. Trends in the numbers of cocaine-related presentations in Euro-DEN Plus sentinel hospitals 2022 to 2023
- Table EDR25-Cocaine-10. Polysubstance toxicity in drug-related deaths cases with cocaine involved, 2022, Spain
- Table EDR25-Stimulants-1. Amphetamine and methamphetamine entrants as a share of all first-time treatment entrants
- Table EDR25-Stimulants-2. Trends in all entrants for synthetic cathinone users
- Table EDR25- Stimulants-3. Synthetic stimulants seizures source data
- Table EDR25-Stimulants-4. Synthetic stimulants market price and purity data
- Table EDR25-Stimulants-5. Synthetic stimulants retail market price and purity data indexed trends (2013=100)
- Table EDR25-Stimulants-6. Trends in the number of synthetic stimulants seizures 2013-2023
- Table EDR25-Stimulants-7. Trends in the quantities of synthetic stimulants seized, tonnes 2013-2023
- Table EDR25-MDMA-2. MDMA markets seizures source data
- Table EDR25-MDMA-5. Trends in the number of MDMA seizures
- Table EDR25-MDMA-4. Trends in the quantity of MDMA seized: tablets
- Table EDR25-MDMA-5. Trends in the quantity of MDMA seized: powder (tonnes)
- Table EDR25-MDMA-6, price and purity or content data
- Table EDR25-MDMA-7. Price and MDMA content indexed trends
- Table EDR25-MDMA-8. MDMA purity or content of samples submitted to drug checking services (percent)
- Table EDR25-MDMA-9. Psychoactive adulterants detected in samples sold as MDMA to users and tested in 12 European drug checking s
- Table EDR25-Heroin-2. Age distribution of never previously treated clients entering treatment with heroin as their primary drug, 2010 and 2023 (%)
- Table EDR25-Heroin-1. Age distribution of all clients entering treatment with heroin as their primary drug, 2010 and 2023 (%)
- Table EDr25-Heroin-3. Trends in first-time heroin treatment entrants
- Table EDR25-Heroin-4. Trends in the main route of administration of clients entering treatment with heroin as primary drug, by treatment status (%)
- Table EDR25-Heroin-5. Heroin markets seizures source data
- Table EDR25-Heroin-6. Trends in the number of heroin seizures (x 1000)
- Table EDR25-Heroin-7. Trends in the quantities of heroin seizures (tonnes)
- Table EDR25-Heroin-8. Price, potency data for cannabis
- Table EDR25-Heroin-9. Price and purity/potency indexed trends
- Table EDR25-Heroin-10a. Proportion of the acute drug toxicity presentations with heroin involved in 2023
- Table EDR25-heroin-10b. Trends in the proportion of the acute drug toxicity presentations with heroin involved in selected hospitals in Europe
- Table EDR25-Heroin-12. Other opioids: number of seizures and quantities seized, 2023
- Table EDR25-NPS-1. Number of new psychoactive substances reported for the first time to the EU Early Warning System, by category, 2005–2024
- Table EDR25-NPS-2. Number of new psychoactive substances reported each year following their first detection in the European Union, by category, 2005–2023
- Table EDR25-NPS-3a. Seizures of new psychoactive substances in the European Union: total number and total quantity of material seized, 2005–2023
- Table EDR25-NPS-3b. Seizures of new psychoactive substances in the European Union: total number of material seized, 2005–2023
- Table EDR25-NPS-4. Number of opioids reported for the first time to the EU Early Warning System, 2009–2024
- Table EDR25-NPS-5. Seizures of new psychoactive substances in the European Union: quantity seized, by substance, 2023
- Table EDR25-NPS-6. Notifications of new psychoactive substances under the terms of Regulation (EC) no 1920/2006 (as amended) and Council Framework Decision 2004/757/JHA (as amended) – 2024
- Table EDR25-BZD-1. Number of formal notifications of benzodiazepines reported to the EU Early Warning System, 2011-24
- Table EDR25-Ketamine-2. Ketamine residues detected in wastewater in selected European cities: most recent data
- Table EDR24-Ketamine-1a. Seizures of ketamine powder in the European Union: total number, 2006–2023
- Table EDR25-ketamine-1b. Seizures of ketamine powder in the European Union: total quantity, 2006-2023
- Table EDR25-Other-8a. Number of seizures and quantity seized of other drugs, European Union
- Table EDR25-Other-8b. Number of seizures and quantity seized of other drugs, European Union, Norway and Türkiye
- Table EDR25-OTHER-9. Proportion of all acute drug toxicity presentations related to GHB/GBL (percent)
- Table EDR25-INJ-1a. Estimated number and prevalence of people who inject drugs, by country (latest available data for each country)
- Table EDR25-INJ-1b. Estimated prevalence (per 1000 people) of people who inject drugs, (latest available data for each country)
- Table EDR25-INJ-2. Trends in injecting among first-time treatment entrants with heroin, cocaine, amphetamine or methamphetamine as primary drug: percentage reporting injecting as main route of administration
- Table EDR25-INJ-3a. European Syringe Collection and Analysis Project Enterprise (ESCAPE) selected data for 2023
- Table EDR25-INJ-3b. ESCAPE project site location data
- Table EDR25-DRID-1. New HIV notifications linked to injecting drug use in the European Union, 2009 to 2023
- Table EDR25-DRID-2. Most-recent HIV outbreaks in Europe among people who inject drugs and the associated injected substance, 2014 to 2023
- Table EDR25-DRID-3. Number of sterile syringes distributed per person who inject drugs per year, 2023 or latest data
- Table EDR25-DRID-4. Availability of needle syringe programmes in Europe at regional level, 2023 or the most recent year available
- Table EDR25-DRID-5a. New HIV cases attributable to injecting drug use
- Table EDR25-DRID-5b. New AIDS cases attributable to injecting drug use
- Table EDR25-DRID-5c. Trends in drug-related HIV: EU and selected countries (cases per million population)
- Table EDR25-DRID-5d. Countries with national data on HCV and HBV
- Table EDR25-DRID-6. Prevalence of active HCV infection among people who inject drugs, by country, 2023 or latest available data
- Table EDR25-DRD-1. Characteristics of drug-induced deaths
- Table EDR25-DRD-1a. Characteristics of drug-induced deaths: gender (percent)
- Table EDR25-DRD-1b. Characteristics of drug-induced deaths: age (by gender)
- Table EDR25-DRD-1c. Characteristics of drug-induced deaths: numbers
- Table EDR25-DRD-2. Age distribution of drug-induced deaths reported in the European Union, Norway and Türkiye in 2023 or the most recent year
- Table EDR25-DRD-3. Proportion of males among drug-induced deaths in the European Union, Norway and Türkiye in 2023, or most recent year (percent)
- Table EDR24-DRD-4. Drug-induced deaths in the European Union: age at death, 2023 or most recent available data (percent)
- Table EDR25-DRD-5. Number of drug-induced deaths reported in the European Union in 2013 and 2023, or the most recent year, by age band
- Table EDR24-DRD-6. Trends in drug-induced deaths in the European Union, Norway and Türkiye
- Table EDR25-DRD-7. Proportion of drug-induced deaths cases with opioids mentioned, 2023 or most recent available data
- Table EDR25-DRD-8. Proportion of drug-induced deaths with benzodiazepines involved, 2020 to 2023, selected countries among those with available information
- Table EDR25-DRD-9. Proportion of drug-induced deaths with mention of alcohol and benzodiazepines
- Table EDR25-DRD-10. Distribution of the cases with heroin mentioned in Austria, Slovenia and Norway in 2023
- Table EDR25-OAT-1. Coverage of opioid agonist treatment in 2023 or the most recent year and 2012/13 (Percent)
- Table EDR25-OAT-2. Clients in opioid agonist treatment
- Table EDR25-OAT-3. Trends in the number in opioid agonist treatment
- Table EDR25-OAT-4. Number of European countries implementing opioid agonist treatment, up to 2024
- Table EDR25-HR-1. Number of European countries implementing harm reduction interventions, up to 2024
- Table EDR25-HR-2. Availability of take-home naloxone in Europe
- Table EDR25-HR-3. Needle and syringe distribution and opioid agonist treatment coverage in relation to WHO 2020 targets, 2023 or latest available estimate
- Table EDR25-HR-4. Location and number of drug consumption facilities throughout Europe 2024
- Table EDR25-HR-5. Availability of drug-related and other health and social care interventions targeting people who use drugs and are in prison, EU+2, 2023
- Table EDR25-Annex-table-1a. High-risk opioid use estimates for population aged 15–64 years
- Table EDR25-Annex-table-1b. Entrants into treatment during the year: opioids clients as a proportion of treatment demands
- Table EDR25-Annex-table-1c. Entrants into treatment during the year: proportion of opioids clients with injection as main route of administration
- Table EDR25-Annex-table-1d. Number of clients in opioid agonist treatment
- Table EDR25-Annex-table-2a. Cocaine prevalence estimates among the general population and school students
- Table EDR25-Annex-table-2b. Entrants into treatment during the year - cocaine clients as a proportion of treatment demands
- Table EDR25-Annex-table-2c. Entrants into treatment during the year: proportion of cocaine clients with injection as main route of administration
- Table EDR25-Annex-table-3a. Amphetamines prevalence estimates among the general population and school students
- Table EDR25-Annex-table-3b. Entrants into treatment during the year - amphetamines clients as a proportion of treatment demands
- Table EDR25-Annex-table-3c. Entrants into treatment during the year: proportion of amphetamines clients with injection as main route of administration
- Table EDR25-Annex-table-4a. MDMA prevalence estimates among the general population and school students
- Table EDR25-Annex-table-4b. Entrants into treatment during the year - MDMA clients as a proportion of treatment demands
- Table EDR25-Annex-table-5a. Cannabis prevalence estimates among the general population and school students
- Table EDR25-Annex-table-5b. Entrants into treatment during the year - cannabis clients as a proportion of treatment demands
- Table EDR25-Annex-table-6. Drug-induced deaths, HIV diagnoses, injecting drug use estimates, syringes distributed through specialised programmes
- Table EDR25-Annex-table-7. Seizures data
- Table EDR25-At-a-glance-1. Drug use in the EU in 2024, at a glance (amphetamines, cannabis, cocaine, MDMA)
- Table EDR25-At-a-glance-1.Heroin and other opioids in the EU in 2024, at a glance